563 related articles for article (PubMed ID: 28600301)
1. Features of optical coherence tomography predictive of choroidal neovascularisation treatment response in pathological myopia in association with fluorescein angiography.
Lee DH; Kang HG; Lee SC; Kim M
Br J Ophthalmol; 2018 Feb; 102(2):238-242. PubMed ID: 28600301
[TBL] [Abstract][Full Text] [Related]
2. CORRESPONDENCE OF LEAKAGE ON FLUORESCEIN ANGIOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY PARAMETERS IN DIAGNOSIS AND MONITORING OF MYOPIC CHOROIDAL NEOVASCULARIZATION TREATED WITH BEVACIZUMAB.
Battaglia Parodi M; Iacono P; Bandello F
Retina; 2016 Jan; 36(1):104-9. PubMed ID: 26166803
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
4. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
[TBL] [Abstract][Full Text] [Related]
5. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
7. Fluorescein Leakage and Optical Coherence Tomography Features of Choroidal Neovascularization Secondary to Pathologic Myopia.
Battaglia Parodi M; Iacono P; Romano F; Bandello F
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3175-3180. PubMed ID: 30025121
[TBL] [Abstract][Full Text] [Related]
8. Structural and optical coherence tomography angiography in myopic choroidal neovascularization: Agreement with conventional fluorescein angiography.
Iacono P; Giorno P; Varano M; Parravano M
Eur J Ophthalmol; 2021 Jan; 31(1):149-157. PubMed ID: 31619075
[TBL] [Abstract][Full Text] [Related]
9. Spectral-Domain Optical Coherence Tomography of Subretinal Hyperreflective Exudation in Myopic Choroidal Neovascularization.
Bruyère E; Caillaux V; Cohen SY; Martiano D; Ores R; Puche N; Souied EH
Am J Ophthalmol; 2015 Oct; 160(4):749-58.e1. PubMed ID: 26164828
[TBL] [Abstract][Full Text] [Related]
10. MICROSTRUCTURAL EFFECTS OF INTRAVITREAL BEVACIZUMAB IN IDIOPATHIC CHOROIDAL NEOVASCULARISATION.
Shah SN; Kang QY; Fan XJ; Shahbaz F
J Ayub Med Coll Abbottabad; 2015; 27(2):259-63. PubMed ID: 26411092
[TBL] [Abstract][Full Text] [Related]
11. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
[TBL] [Abstract][Full Text] [Related]
12. Fluorescein angiography and spectral-domain optical coherence tomography for monitoring anti-VEGF therapy in myopic choroidal neovascularization.
Iacono P; Battaglia Parodi M; Papayannis A; Kontadakis S; Da Pozzo S; Cascavilla ML; La Spina C; Varano M; Bandello F
Ophthalmic Res; 2014; 52(1):25-31. PubMed ID: 24861045
[TBL] [Abstract][Full Text] [Related]
13. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
14. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
Retina; 2007; 27(6):707-12. PubMed ID: 17621179
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab.
Ladaique M; Dirani A; Ambresin A
Klin Monbl Augenheilkd; 2015 Apr; 232(4):542-7. PubMed ID: 25902117
[TBL] [Abstract][Full Text] [Related]
16. APPLICATION OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY TO ASSESS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN MYOPIC CHOROIDAL NEOVASCULARIZATION.
Cheng Y; Li Y; Huang X; Qu Y
Retina; 2019 Apr; 39(4):712-718. PubMed ID: 29256987
[TBL] [Abstract][Full Text] [Related]
17. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.
Ruiz-Moreno JM; Montero JA; Amat-Peral P
Graefes Arch Clin Exp Ophthalmol; 2011 Apr; 249(4):595-9. PubMed ID: 21234588
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results.
Peiretti E; Vinci M; Fossarello M
Can J Ophthalmol; 2012 Feb; 47(1):28-33. PubMed ID: 22333848
[TBL] [Abstract][Full Text] [Related]
19. Microvasculature Changes of Myopic Choroidal Neovascularization and the Predictive Value of Feeder Vessel Disappearance after Ranibizumab Treatment Revealed Using Optical Coherence Tomography Angiography.
Giorno P; Iacono P; Scarinci F; Di Renzo A; Varano M; Parravano M
Ophthalmologica; 2020; 243(4):263-270. PubMed ID: 31838464
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
